On 15-17 May, the EPAD (European Prevention of Alzheimer’s Dementia) project General Assembly (GA) took place in Stockholm, Sweden, under the banner “From Delivery to Data”. EPAD is co-coordinated by Craig Ritchie, Professor of the Psychiatry of Ageing at the University of Edinburgh and Dr Serge Van der Geyten, Director for Neuroscience External Affairs at Janssen Pharmaceutica.

The stated aims of this year’s GA were to:

• Create an environment for the sustained success of the project
• Expand and “future proof” the Longitudinal Cohort Study (LCS)
• Build the Proof-of-Concept (PoC) Platform.

On the second day, the EPAD GA gathered for its official inauguration by HRH Queen Silvia of Sweden, who welcomed delegates to Stockholm and the first session of the day on “the future of AD research”.

Gill Farrar (pictured) from GE Healthcare was invited to do a presentation on EPAD’s collaboration with its sister project AMYPAD. There, Gill, AMYPAD co-lead, gave also an overview of the project partners and objectives.

To keep up to date with EPAD’s progress follow @IMI_EPAD on Twitter, visit https://fr-fr.facebook.com/IMIEPAD/ and visit the website http://ep-ad.org/.

The EPAD project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.